13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurochemists
Neurochemists explore the chemical processes that occur in the brain, focusing on how neurotransmitters, hormones, and other chemicals influence brain function and behavior. They investigate how these chemicals are synthesized, released, and regulated within the nervous system, examining their roles in mood regulation, cognition, and motor control. Neurochemistry plays a critical role in understanding disorders such as depression, anxiety, schizophrenia, and Parkinson's disease, all of which involve imbalances in brain chemistry. Neurochemists also study how drugs, both therapeutic and recreational, affect the brain’s chemical environment and contribute to neurological and psychiatric conditions. Their research provides valuable insights into developing more effective medications, targeting specific neurotransmitter systems to treat conditions like epilepsy, bipolar disorder, and addiction. Furthermore, neurochemists study the molecular mechanisms of neurodegenerative diseases, such as Alzheimer's, where protein misfolding and deposition contribute to cognitive decline. Their work in neurochemical signaling and receptor function has significant implications for drug development, as they aim to create more selective, personalized treatments with fewer side effects. Additionally, neurochemists are involved in studying the impact of diet and lifestyle on brain chemistry, which can influence brain aging, cognitive decline, and overall mental health.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States